Janux Therapeutics Inc (JANX)
Healthcare
Biotechnology
15.20 $
-2.6%
vs. previous close
Closing price · As of: 31. Jul 2026
Janux Therapeutics Inc (JANX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -82 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -3.8 | -4.4 | -17 | -43 | -51 | -44 | -82 | |
| 0.0 | 0.0 | 0.1 | 0.8 | 2.0 | 2.1 | 2.0 | |
| 0.0 | 0.1 | 6.9 | 17 | 20 | 33 | 40 | |
| 0.2 | 2.0 | 6.7 | 17 | – | – | – | |
| -0.1 | 0.4 | 8.8 | 4.3 | -6.6 | 0.7 | 6.7 | |
| 1.5 | 1.5 | 1.5 | 6.4 | 1.9 | 0.4 | 1.0 | |
| -341 | -341 | -341 | 58 | -41 | -258 | -301 | |
| – | – | 204 | – | – | – | -0.3 | |
| 4.0 | 2.5 | 181 | 23 | – | – | – | |
| 4.0 | 12 | 387 | 0.5 | 60 | 713 | 4.9 | |
| 0.2 | 7.2 | 29 | 16 | -32 | 411 | -378 | |
| -3.8 | -4.4 | -18 | -49 | -52 | -44 | -83 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.